Q-Linea

The two large hospitals are both reviewing their workstreams for the treatment of patients with bloodstream infections and decided to explore rapid AST from positive blood culture to improve clinical care. A combined total of 154 patients and contrived samples were investigated and compared with the current standard of care. Results showed very good overall concordance with a significant reduction in time to optimal therapy. Results are expected to be published.

Mark Reed, General Manager at Pro-Lab Diagnostics commented:” We are very pleased to see another strong outcome in clinical evaluations and proceed with both sites into commercial discussions on how to implement ASTar into their clinical routine.  There is a growing interest amongst our customers in the UK to investigate these novel technologies fueled by the increasing rates of antimicrobial resistance and political initiatives to counteract this emerging threat.”